Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Paul T. Heath; Eva P. Galiza; David N. Baxter; Marta Boffito; Duncan Browne; Fiona Burns; David R. Chadwick; Rebecca Clark; Catherine Cosgrove; James Galloway; Anna L. Goodman; Amardeep Heer; Andrew Higham; Shalini Iyengar; Arham Jamal; Christopher Jeanes; Philip A. Kalra; Christina Kyriakidou; Daniel F. McAuley; Agnieszka Meyrick; Angela M. Minassian; Jane Minton; Patrick Moore; Imrozia Munsoor; Helen Nicholls; Orod Osanlou; Jonathan Packham; Carol H. Pretswell; Alberto San Francisco Ramos; Dinesh Saralaya; Ray P. Sheridan; Richard Smith; Roy L. Soiza; Pauline A. Swift; Emma C. Thomson; Jeremy Turner; Marianne E. Viljoen; Gary Albert; Iksung Cho; Filip Dubovsky; Greg Glenn; Joy Rivers; Andreana Robertson; Kathy Smith; Seth Toback

Journal ArticleOPEN ACCESS

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Heath P
Galiza E
Baxter D
et al.

New England Journal of Medicine (2021) 385(13) 1172-1183

DOI: 10.1056/nejmoa2107659

795Citations

928Readers

Get full text

Abstract

Abstract Background Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) th...

Cite

CITATION STYLE

APA

Heath, P. T., Galiza, E. P., Baxter, D. N., Boffito, M., Browne, D., Burns, F., … Toback, S. (2021). Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. New England Journal of Medicine, 385(13), 1172–1183. https://doi.org/10.1056/nejmoa2107659

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Abstract

Cite

Register to see more suggestions